US 12,588,698 B2 · Aerosolizable nicotine-containing formulations

Abstract

Nicotine-containing formulations for electric/electronic nicotine delivery systems are disclosed, containing both nicotine at relatively much higher concentrations, typically at least 25% by weight of total formulation weight, w/w, and in many cases as much as 40-50% w/w, than is typical for conventional nicotine containing formulations, which only contain about 2-4% w/w nicotine. The formulations also include a biologically and pharmaceutically acceptable mono- or di-carboxylic organic acid, such as benzoic acid, salicylic acid and most preferably lactic acid also at relatively high w/w concentrations. One or more nicotine salts may be created and be extant within the formulations, which not only mitigates against the loss of nicotine to the atmosphere through natural volatility and evaporation, but also markedly increases the surface energy of the formulations created, and the globules of formulations deposited on a heating substrate are much more cohesive and much less likely to migrate through wetting over the substrate.

Claims17

Dependent claims

An aerosolisable formulation comprising

Between about 25-50%, w/w free-base nicotine,
Between about 15-35% w/w of lactic acid, or some combination of lactic acid and one or more pharmaceutically and biologically acceptable mono- or di-carboxylic organic acids,
Between about 60-10% w/w of one or some combination of two or more-pharmaceutically and biologically acceptable liquid excipients, and optionally
Between about 0-5% w/w water.

1 more element

Dependencies are inferred from the claim text.

Aerosolizable nicotine-containing formulations

Life of this patent

Aerosolizable nicotine-containing formulations

Life of this patent

Abstract

Claims17